European regulators are considering withdrawing market authorizations for certain hair loss and enlarged prostate treatments, including Organon’s (NYSE:OGN) Propecia, over concerns they can trigger ...
A four-year study of more than 8,000 men between the ages of 50 to 75 who had an elevated risk for developing prostate cancer found that those who took the drug dutasteride (sold as Avodart) were less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results